Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri.
Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.
JAMA Otolaryngol Head Neck Surg. 2020 Jan 1;146(1):50-56. doi: 10.1001/jamaoto.2019.3277.
The optimal treatment strategy for patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) of the base of the tongue (BOT) has not been sufficiently studied.
To investigate the rate of and risk factors for occult contralateral nodal disease in patients with HPV-related BOT OPSCC undergoing transoral surgery and bilateral neck dissections.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series reviewed the medical records of patients with HPV-related BOT OPSCC who underwent transoral surgery and bilateral neck dissections from January 1, 2002, through December 31, 2018, at the tertiary care center of Washington University School of Medicine in St Louis. Patients had a median follow-up of 30.0 months (interquartile range, 11.0-60.4 months). Patients with recurrent disease or multiple synchronous OPSCC primary tumors were excluded for a total of 89 patients. Data were analyzed from January 1 through June 1, 2019.
The primary outcome was the rate of contralateral occult nodal disease. Secondary outcomes were potential risk factors for contralateral occult nodal disease and regional recurrence rates.
Eighty-nine patients were included in the series, of whom 81 (91.0%) were men. The mean (SD) age was 60 (9) years. Overall, 34 patients (38.2%) had pathologic contralateral nodal metastases. Seventy patients had no clinical evidence of contralateral nodal disease. Of these 70, occult nodes were identified in 15 (21.4%). Risk of contralateral disease was higher when the primary tumor crossed midline (odds ratio, 6.23; 95% CI, 1.71-22.77). Of the 55 patients with no occult disease identified, only 2 (3.6%) received radiotherapy to the contralateral neck, and no regional recurrence of disease was noted.
Given the rate of occult contralateral nodal disease of 21.4%, it appears that contralateral elective neck dissection or radiotherapy should be recommended in patients with HPV-related BOT OPSCC. Patients with a pathologically negative result of contralateral neck dissection may not benefit from radiotherapy to that nodal basin. Future prospective investigations should evaluate functional and oncologic outcomes of contralateral elective neck dissection compared with elective radiotherapy in the contralateral neck for HPV-related BOT OPSCC.
人乳头瘤病毒(HPV)相关口咽鳞状细胞癌(OPSCC)舌根(BOT)的最佳治疗策略尚未得到充分研究。
调查经口手术和双侧颈部解剖治疗 HPV 相关 BOT OPSCC 患者隐匿性对侧淋巴结疾病的发生率和危险因素。
设计、地点和参与者:这项回顾性病例系列研究回顾了 2002 年 1 月 1 日至 2018 年 12 月 31 日期间在圣路易斯华盛顿大学医学院三级护理中心接受经口手术和双侧颈部解剖治疗的 HPV 相关 BOT OPSCC 患者的病历。患者的中位随访时间为 30.0 个月(四分位距,11.0-60.4 个月)。为了总共排除 89 例复发性疾病或多个同步 OPSCC 原发性肿瘤的患者。数据分析于 2019 年 1 月 1 日至 6 月 1 日进行。
主要结局是对侧隐匿性淋巴结疾病的发生率。次要结局是对侧隐匿性淋巴结疾病的潜在危险因素和区域复发率。
该系列共纳入 89 例患者,其中 81 例(91.0%)为男性。平均(SD)年龄为 60(9)岁。总体而言,34 例患者(38.2%)存在病理性对侧淋巴结转移。70 例患者无对侧淋巴结疾病的临床证据。其中,70 例中有 15 例(21.4%)发现隐匿性淋巴结。当原发肿瘤越过中线时,对侧疾病的风险更高(比值比,6.23;95%CI,1.71-22.77)。在 55 例未发现隐匿性疾病的患者中,只有 2 例(3.6%)接受了对侧颈部放疗,且未观察到疾病的局部复发。
鉴于隐匿性对侧淋巴结疾病的发生率为 21.4%,似乎 HPV 相关 BOT OPSCC 患者应推荐对侧选择性颈部解剖或放疗。对侧颈部病理阴性的患者可能不需要对该淋巴结区域进行放疗。未来的前瞻性研究应评估 HPV 相关 BOT OPSCC 患者对侧选择性颈部解剖与对侧选择性放疗在功能和肿瘤学结果方面的差异。